BillionToOne, Inc. (BLLN) — Stock Score Summary

BillionToOne, Inc. (BLLN) has a MoatMap StockRank of 26/100 based on Quality (68/100), Value (12/100), and Momentum (33/100) factor scores. The current signal is SELL. BillionToOne, Inc. (US, Healthcare) is a small-cap biotech, highly speculative and dependent on specific drug development, not macro themes. It lacks the characteristics of a quality compounder with an uncopyable moat based on broad economic trends.

BillionToOne, Inc. is a molecular diagnostics company leveraging its proprietary quantitative molecular counting technology to develop highly accurate non-invasive tests for prenatal conditions and early cancer detection. Its competitive advantage lies in its unique technology, which provides unprecedented resolution and sensitivity, enabling precise detection of genetic variations from small biological samples. The company is positioned to disrupt traditional genetic and oncology diagnostics with its innovative platform.

Key Financial Metrics

Price$97.80
Market Cap$4.5B
P/E (TTM)156.44
P/E (Forward)82.02
Price/Book7.68
Return on Equity8.7%
Return on Invested Capital1.3%
Debt/Equity28.52
Gross Margin70.4%
Operating Margin16.5%
Revenue Growth83.8%
Free Cash Flow$17M

BillionToOne, Inc. operates in the Diagnostics & Research industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is BillionToOne, Inc.’s (BLLN) StockRank?
MoatMap’s StockRank for BillionToOne, Inc. (BLLN) is 26/100, with a Sell signal. It is a composite of Quality (68), Value (12), and Momentum (33) factor ranks across MoatMap’s 19,000+ stock universe.
Does BillionToOne, Inc. have an economic moat?
BillionToOne, Inc. (BLLN) has a Quality factor score of 68/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is BillionToOne, Inc. a buy, hold, or sell?
MoatMap’s current signal for BillionToOne, Inc. (BLLN) is Sell, based on a StockRank of 26/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is BillionToOne, Inc. in?
BillionToOne, Inc. (BLLN) operates in the Healthcare sector, specifically the Diagnostics & Research industry (United States).
Browse all ranked stocksBLLN deep dive reportAI ChampionsHow we score stocksSense-check another stock